ReviewRheumatic diseases clinics of North America2010
Cell-cell interactions in rheumatoid arthritis synovium.
Review in Rheumatic diseases clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 83 citations in OpenAlex.
- OX40L in endothelial cells promotes temporomandibular joint subchondral bone angiogenesis and osteoclastogenesis in mice.Bone & joint research · 2026Article
- Lutein Attenuates Synovial Hyperplasia, Cartilage Loss, and Bone Erosion by Suppressing Inflammatory Pathways in Rheumatoid Arthritis.International journal of medical sciences · 2026Article
- A 10-year knowledge mapping of T cells in rheumatoid arthritis: A bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Multiscale, mechanistic model of Rheumatoid Arthritis to enable decision making in late stage drug development.NPJ systems biology and applications · 2024Article
- Citrullinated and malondialdehyde-acetaldehyde modified fibrinogen activates macrophages and promotes an aggressive synovial fibroblast phenotype in patients with rheumatoid arthritis.Frontiers in immunology · 2023Article
- Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1.The Journal of clinical investigation · 2022Article
- Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications.Nano convergence · 2022Review
- Immunosuppression in Rheumatologic and Auto-immune Disease.Handbook of experimental pharmacology · 2022Article
- Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases.Nature reviews. Rheumatology · 2021Review
- Macrophages: The Good, the Bad, and the Gluttony.Frontiers in immunology · 2021Review
- Reprogramming of synovial macrophage metabolism by synovial fibroblasts under inflammatory conditions.Cell communication and signaling : CCS · 2020Article
- Anti-arthritic and anti- inflammatory effects of extract and fractions of Malva parviflora in a mono- arthritis model induced with kaolin/carrageenan.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes.Nature reviews. Rheumatology · 2020Review
- Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis.Journal of translational autoimmunity · 2020Article
- Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis: A Brief Review.Cells · 2019Review
- Angiogenic and Arthritogenic Properties of the Soluble Form of CD13.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Inhibition of MMPs and ADAM/ADAMTS.Biochemical pharmacology · 2019Review
- Flavonoids: Broad Spectrum Agents on Chronic Inflammation.Biomolecules & therapeutics · 2019Review
- Review
- The role of the JAK/STAT signal pathway in rheumatoid arthritis.Therapeutic advances in musculoskeletal disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Understanding the pathogenesis of joint inflammation and destruction in rheumatoid arthritis involves dissection of the cellular and molecular interactions that occur in synovial tissue. Development of effective targeted therapies has been based on progress in achieving such insights. Safer and more specific approaches to treatment could flow from discovery of cell-cell interaction pathways that are specific to inflammation of the joint and less important in the defense against systemic infection. This article highlights selected cell-cell interactions in rheumatoid arthritis synovium that may be worthy of evaluation as future therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.